138 related articles for article (PubMed ID: 2229778)
21. Interactions of nifedipine with the renovascular effects of endothelin in humans.
Kaasjager KA; van Rijn HJ; Koomans HA; Rabelink TJ
J Pharmacol Exp Ther; 1995 Oct; 275(1):306-11. PubMed ID: 7562563
[TBL] [Abstract][Full Text] [Related]
22. Vascular effects of endothelin-1 in humans and influence of calcium channel blockade.
Kiowski W; Linder L; Erne P
J Hypertens Suppl; 1994 Jan; 12(1):S21-6. PubMed ID: 8207561
[TBL] [Abstract][Full Text] [Related]
23. Attenuation of the vasoconstrictor action of neuropeptide-Y by calcium-channel blockers.
Aizawa Y; Niwano S; Aizawa M; Tamura M; Shibata A
Angiology; 1989 Oct; 40(10):890-4. PubMed ID: 2802259
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of calcium channel antagonists in the amelioration of radial artery vasospasm.
Bond BR; Zellner JL; Dorman BH; Multani MM; Kratz JM; Crumbley AJ; Crawford FA; Spinale FG
Ann Thorac Surg; 2000 Apr; 69(4):1035-40; discussion 1040-1. PubMed ID: 10800790
[TBL] [Abstract][Full Text] [Related]
25. Myocardial perfusion distal to an acute or chronic coronary artery occlusion: effects of diltiazem and nifedipine.
Zyvoloski MG; Brooks HL; Gross GJ; Warltier DC
J Pharmacol Exp Ther; 1982 Aug; 222(2):494-500. PubMed ID: 7097568
[TBL] [Abstract][Full Text] [Related]
26. Selective improvement in subendocardial perfusion distal to a flow-limiting coronary artery stenosis: effects of the new calcium channel blocking agent, FR 34235, nifedipine and diltiazem.
Gross GJ; Warltier DC
J Pharmacol Exp Ther; 1984 Mar; 228(3):531-6. PubMed ID: 6707908
[TBL] [Abstract][Full Text] [Related]
27. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans.
Pernow J; Kaijser L; Lundberg JM; Ahlborg G
Circulation; 1996 Nov; 94(9):2077-82. PubMed ID: 8901654
[TBL] [Abstract][Full Text] [Related]
28. Effects of calcium channel blockers on the response to endothelin-1, bradykinin and sodium nitroprusside in porcine ciliary arteries.
Meyer P; Lang MG; Flammer J; Lüscher TF
Exp Eye Res; 1995 May; 60(5):505-10. PubMed ID: 7615016
[TBL] [Abstract][Full Text] [Related]
29. Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C.
McNair LL; Salamanca DA; Khalil RA
Hypertension; 2004 Apr; 43(4):897-904. PubMed ID: 14981072
[TBL] [Abstract][Full Text] [Related]
30. Coronary vasomotor disorders during hypoxia-reoxygenation: do calcium channel blockers play a protective role?
Ordoñez Fernández A; Hernandez Fernandez A; Borrego Dominguez JM; Gutierrez Carretero E; Muñoz García J; Prieto Rodriguez MF; Viloria Peñas MM
Res Exp Med (Berl); 2000 Jun; 199(6):319-31. PubMed ID: 10945650
[TBL] [Abstract][Full Text] [Related]
31. Effects of endothelin, calcium channel blockade and EDRF inhibition on the contractility of human uteroplacental arteries.
Fried G; Liu YA
Acta Physiol Scand; 1994 Aug; 151(4):477-84. PubMed ID: 7976421
[TBL] [Abstract][Full Text] [Related]
32. Coronary vasoconstriction mediated by endothelin-1 in neonates. Reversal by nitroglycerin.
McGowan FX; Davis PJ; Siewers RD; del Nido PJ
J Thorac Cardiovasc Surg; 1995 Jan; 109(1):88-97; discussion 97-8. PubMed ID: 7815811
[TBL] [Abstract][Full Text] [Related]
33. Effect of KRN2391, a novel vasodilator, on endothelin-1-induced contraction of porcine coronary artery: comparison with cromakalim, nitroglycerin and nifedipine.
Miwa A; Kasai H; Motoki K; Jinno Y; Yokoyama T; Fukushima H; Ogawa N
Arch Int Pharmacodyn Ther; 1993; 326():52-61. PubMed ID: 8185413
[TBL] [Abstract][Full Text] [Related]
34. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.
Millard RW; Lathrop DA; Grupp G; Ashraf M; Grupp IL; Schwartz A
Am J Cardiol; 1982 Feb; 49(3):499-506. PubMed ID: 6277175
[TBL] [Abstract][Full Text] [Related]
35. Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo.
Golino P; Buja LM; Yao SK; McNatt J; Willerson JT
J Am Coll Cardiol; 1990 Mar; 15(3):718-26. PubMed ID: 2105989
[TBL] [Abstract][Full Text] [Related]
36. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor.
Cannan CR; Burnett JC; Brandt RR; Lerman A
Circulation; 1995 Dec; 92(11):3312-7. PubMed ID: 7586319
[TBL] [Abstract][Full Text] [Related]
37. The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.
Soward AL; Vanhaleweyk GL; Serruys PW
Drugs; 1986 Jul; 32(1):66-101. PubMed ID: 2874975
[TBL] [Abstract][Full Text] [Related]
38. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765.
Grover GJ; Parham CS; Sleph PG; Moreland S
J Pharmacol Exp Ther; 1989 Dec; 251(3):1020-5. PubMed ID: 2481028
[TBL] [Abstract][Full Text] [Related]
39. Tetramethylpyrazine, a Chinese drug, blocks coronary vasoconstriction by endothelin-1 and decreases plasma endothelin-1 levels in experimental animals.
Zeng Z; Zhu W; Zhou X; Jin Z; Liu H; Chen X; Pan J; Demura H; Naruse M; Shi Y
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S313-6. PubMed ID: 9595468
[TBL] [Abstract][Full Text] [Related]
40. Exercise training alters the Ca2+ and contractile responses of coronary arteries to endothelin.
Bowles DK; Laughlin MH; Sturek M
J Appl Physiol (1985); 1995 Mar; 78(3):1079-87. PubMed ID: 7775301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
